Pos. |
WT |
Mut |
AA |
Mut |
Comp |
Name |
NB |
Cancer |
Ref |
Comments |
237 |
ATG |
ATA |
Met |
Ile |
SM |
WI-L2-NS |
123 |
B-cell Leukemia |
637 |
Controversy with other publications |
330 |
CTT |
CAT |
Leu |
His |
SM |
WI-L2-NS |
4 |
B-cell Leukemia |
769 |
Controversy with other publications |
126 |
TAC |
TAG |
Tyr |
Stop |
SM |
EJ |
14 |
Bladder carcinoma |
689 |
Controversy with other publications |
164 |
AAG |
GAG |
Lys |
Glu |
SM |
EJ |
25 |
Bladder carcinoma |
729 |
Controversy with other publications |
76 |
GCA |
del76 |
Ala |
Fs. |
SM |
FHS 738B1 |
1 |
Bladder carcinoma |
561 |
Single report |
365 |
CAC |
CGC |
His |
Arg |
SM |
HT-1197 |
1 |
Bladder carcinoma |
561 |
wt in COSMIC |
250 |
CCC |
CTC |
Pro |
Leu |
SM |
HT-1376 |
53 |
Bladder carcinoma |
561 |
Confirmed in two other publications |
261 |
AGT |
del137 |
Ser |
Fs. |
DMU |
J82 |
1 |
Bladder carcinoma |
2249 |
Controversy with other publications Deletion of exon 8 |
271 |
GAG |
AAG |
Glu |
Lys |
MM |
J82 |
38 |
Bladder carcinoma |
561 |
Controversy with other publications undocumented 4th mutation (deletion 210 bp) |
271 |
GAG |
AAG |
Glu |
Lys |
MM |
J82 |
38 |
Bladder carcinoma |
729 |
Controversy with other publications |
274 |
GTT |
TTT |
Val |
Phe |
MM |
J82 |
32 |
Bladder carcinoma |
561 |
Controversy with other publications undocumented 4th mutation (deletion 210 bp) |
274 |
GTT |
TTT |
Val |
Phe |
MM |
J82 |
32 |
Bladder carcinoma |
729 |
Controversy with other publications |
320 |
AAG |
AAC |
Lys |
Asn |
MM |
J82 |
5 |
Bladder carcinoma |
561 |
Controversy with other publications undocumented 4th mutation (deletion 210 bp) |
320 |
AAG |
AAC |
Lys |
Asn |
DMU |
J82 |
5 |
Bladder carcinoma |
2249 |
Controversy with other publications |
320 |
AAG |
AAC |
Lys |
Asn |
MM |
J82 |
5 |
Bladder carcinoma |
729 |
Controversy with other publications |
183 |
TCA |
TGA |
Ser |
Stop |
DMU |
RT-112 |
29 |
Bladder carcinoma |
2249 |
Controversy with other publications |
248 |
CGG |
CAG |
Arg |
Gln |
SM |
RT-112 |
883 |
Bladder carcinoma |
1733 |
Controversy with other publications |
248 |
CGG |
CAG |
Arg |
Gln |
DMU |
RT-112 |
883 |
Bladder carcinoma |
2249 |
Controversy with other publications |
110 |
CGT |
CTT |
Arg |
Leu |
SM |
SD |
28 |
Bladder carcinoma |
294 |
Controversy with other publications |
116 |
TCT |
TGT |
Ser |
Cys |
SM |
SD |
3 |
Bladder carcinoma |
689 |
Controversy with other publications |
126 |
TAC |
TAG |
Tyr |
Stop |
SM |
T-24 |
14 |
Bladder carcinoma |
689 |
Controversy with other publications |
126 |
TAC |
del3a |
Tyr |
InF |
SM |
T-24 |
1 |
Bladder carcinoma |
561 |
Controversy with other publications |
126 |
TAC |
TAG |
Tyr |
Stop |
DMU |
VM-CUB-1 |
14 |
Bladder carcinoma |
2249 |
Controversy with other publications |
175 |
CGC |
CAC |
Arg |
His |
SM |
VM-CUB-1 |
1187 |
Bladder carcinoma |
689 |
Controversy with other publications |
175 |
CGC |
CAC |
Arg |
His |
DMU |
VM-CUB-1 |
1187 |
Bladder carcinoma |
2249 |
Controversy with other publications |
158 |
CGC |
CTC |
Arg |
Leu |
DMU |
VM-CUB-2 |
92 |
Bladder carcinoma |
689 |
Controversy with other publications |
158 |
CGC |
CTC |
Arg |
Leu |
SM |
VM-CUB-2 |
92 |
Bladder carcinoma |
294 |
Controversy with other publications |
163 |
TAC |
TGC |
Tyr |
Cys |
DMU |
VM-CUB-2 |
140 |
Bladder carcinoma |
689 |
Controversy with other publications |
246 |
ATG |
del1c |
Met |
Fs. |
SM |
BT-483 |
1 |
Breast carcinoma |
2029 |
Controversy with other publications |
246 |
ATG |
ATA |
Met |
Ile |
SM |
BT-483 |
33 |
Breast carcinoma |
2091 |
Controversy with other publications |
204 |
GAG |
ins7c |
Glu |
Fs. |
SM |
MDA-MB-436 |
1 |
Breast carcinoma |
2029 |
Controversy with other publications |
273 |
CGT |
CAT |
Arg |
His |
SM |
MDA-MB-436 |
780 |
Breast carcinoma |
1367 |
Controversy with other publications |
213 |
CGA |
TGA |
Arg |
Stop |
SM |
DAUDI |
306 |
Burkitt lymphoma |
44 |
Controversy with other publications |
266 |
GGA |
GAA |
Gly |
Glu |
SM |
DAUDI |
74 |
Burkitt lymphoma |
2249 |
Controversy with other publications |
158 |
CGC |
CAC |
Arg |
His |
SM |
ST486 |
105 |
Burkitt lymphoma |
44 |
Consensus based on three puublications. Controversy with other publications Second mutation found by COSMIC |
158 |
CGC |
CAC |
Arg |
His |
DMU |
ST486 |
105 |
Burkitt lymphoma |
2249 |
Controversy with other publications. Excluded from the consensus |
239 |
AAC |
GAC |
Asn |
Asp |
DMU |
ST486 |
53 |
Burkitt lymphoma |
2249 |
Controversy with other publications. Excluded from the consensus |
234 |
TAC |
TGC |
Tyr |
Cys |
SM |
CaR-1 |
133 |
Colorectal carcinoma |
1006 |
Controversy with other publications. wt in COSMIC |
272 |
GTG |
ATG |
Val |
Met |
SM |
CaR-1 |
105 |
Colorectal carcinoma |
2051 |
Controversy with other publications. wt in COSMIC |
103 |
TAC |
del27 |
Tyr |
InF |
SM |
COLO-205 |
1 |
Colorectal carcinoma |
492 |
Controversy with other publications |
266 |
GGA |
GAA |
Gly |
Glu |
SM |
COLO-205 |
74 |
Colorectal carcinoma |
1018 |
Controversy with other publications |
153 |
CCC |
GCC |
Pro |
Ala |
SM |
HCT-15 |
5 |
Colorectal carcinoma |
1018 |
Controversy with other publications |
241 |
TCC |
TTC |
Ser |
Phe |
SM |
HCT-15 |
101 |
Colorectal carcinoma |
2251 |
Controversy with other publications |
72 |
CCC |
del1b |
Pro |
Fs. |
SM |
KM12 |
1 |
Colorectal carcinoma |
2249 |
Controversy with other publications |
179 |
CAT |
CGT |
His |
Arg |
SM |
KM12 |
146 |
Colorectal carcinoma |
1018 |
Controversy with other publications |
156 |
CGC |
del1a |
Arg |
Fs. |
DMU |
RL95-2 |
3 |
Endometrial tumor |
1625 |
Controversy with other publications |
218 |
GTG |
del3 |
Val |
InF |
SM |
RL95-2 |
2 |
Endometrial tumor |
64 |
Controversy with other publications |
218 |
GTG |
del3a |
Val |
InF |
DMU |
RL95-2 |
3 |
Endometrial tumor |
1625 |
Controversy with other publications |
179 |
CAT |
CGT |
His |
Arg |
SM |
KYSE-450 |
146 |
Esophageal SCC |
634 |
Controversy with other publications |
339 |
GAG |
TAG |
Glu |
Stop |
SM |
KYSE-450 |
12 |
Esophageal SCC |
2249 |
Controversy with other publications |
241 |
TCC |
del32c |
Ser |
Fs. |
SM |
KYSE-510 |
1 |
Esophageal SCC |
634 |
Controversy with other publications |
343 |
GAG |
TAG |
Glu |
Stop |
SM |
KYSE-510 |
5 |
Esophageal SCC |
2249 |
Controversy with other publications |
110 |
CGT |
CTT |
Arg |
Leu |
SM |
TE-11 |
28 |
Esophageal SCC |
1006 |
Controversy with other publications. wt in COSMIC |
237 |
ATG |
ATT |
Met |
Ile |
SM |
TE-11 |
52 |
Esophageal SCC |
1144 |
Controversy with other publications. wt in COSMIC |
251 |
ATC |
CTC |
Ile |
Leu |
DMU |
MKN-74 |
5 |
Gastric carcinoma |
1006 |
Controversy with other publications. wt in COSMIC |
251 |
ATC |
CTC |
Ile |
Leu |
SM |
MKN-74 |
5 |
Gastric carcinoma |
94 |
Controversy with other publications. wt in COSMIC |
271 |
GAG |
GCG |
Glu |
Ala |
DMU |
MKN-74 |
3 |
Gastric carcinoma |
1006 |
Controversy with other publications. wt in COSMIC |
342 |
CGA |
del1a |
Arg |
Fs. |
SM |
SF-539 |
5 |
Gliomas |
2249 |
Controversy with other publications |
277 |
TGT |
del30 |
Cys |
InF |
SM |
UM-SCC-14 |
2 |
Head and Neck SCC |
1019 |
Controversy with other publications |
277 |
TGT |
del30 |
Cys |
InF |
DMU |
UM-SCC-14 |
2 |
Head and Neck SCC |
1636 |
Controversy with other publications |
280 |
AGA |
AGT |
Arg |
Ser |
DMU |
UM-SCC-14 |
14 |
Head and Neck SCC |
1636 |
Controversy with other publications |
244 |
GGC |
GCC |
Gly |
Ala |
SM |
HLE |
10 |
Hepatocellular carcinoma |
1069 |
Controversy with other publications |
249 |
AGG |
AGC |
Arg |
Ser |
SM |
HLE |
34 |
Hepatocellular carcinoma |
230 |
Controversy with other publications |
272 |
GTG |
ATG |
Val |
Met |
SM |
HLE |
105 |
Hepatocellular carcinoma |
1006 |
Controversy with other publications |
237 |
ATG |
AAG |
Met |
Lys |
DMU |
SK-LMS-1 |
11 |
Leyomyosarcoma |
2198 |
Controversy with other publications |
245 |
GGC |
AGC |
Gly |
Ser |
SM |
SK-LMS-1 |
440 |
Leyomyosarcoma |
14 |
Controversy with other publications |
245 |
GGC |
AGC |
Gly |
Ser |
DMU |
SK-LMS-1 |
440 |
Leyomyosarcoma |
2198 |
Controversy with other publications |
175 |
CGC |
CAC |
Arg |
His |
DMU |
SK-UT-1 |
1187 |
Leyomyosarcoma |
2249 |
Controversy with other publications |
175 |
CGC |
CAC |
Arg |
His |
SM |
SK-UT-1 |
1187 |
Leyomyosarcoma |
14 |
Controversy with other publications |
248 |
CGG |
CAG |
Arg |
Gln |
DMU |
SK-UT-1 |
883 |
Leyomyosarcoma |
2249 |
Controversy with other publications |
187 |
GGT |
del111 |
Gly |
InF |
SM |
EKVX |
1 |
Lung (NSCLC) |
1018 |
Controversy with other publications |
203 |
GTG |
GTT |
Val |
Val |
SM |
EKVX |
2 |
Lung (NSCLC) |
2249 |
Controversy with other publications |
204 |
GAG |
TAG |
Glu |
Stop |
SM |
EKVX |
46 |
Lung (NSCLC) |
2249 |
Controversy with other publications |
47 |
CCG |
CTG |
Pro |
Leu |
SM |
NCI-H1373 |
3 |
Lung (NSCLC) |
106 |
Controversy with other publications |
34 |
CCC |
ins1 |
Pro |
Fs. |
DMU |
NCI-H157 |
1 |
Lung (NSCLC) |
1382 |
Controversy with other publications |
282 |
CGG |
CCG |
Arg |
Pro |
SM |
NCI-H157 |
21 |
Lung (NSCLC) |
2021 |
Controversy with other publications |
298 |
GAG |
TAG |
Glu |
Stop |
SM |
NCI-H157 |
71 |
Lung (NSCLC) |
92 |
Controversy with other publications |
298 |
GAG |
TAG |
Glu |
Stop |
DMU |
NCI-H157 |
71 |
Lung (NSCLC) |
1382 |
Controversy with other publications |
285 |
GAG |
AAG |
Glu |
Lys |
SM |
NCI-H1703 |
165 |
Lung (NSCLC) |
92 |
Controversy with other publications |
209 |
AGA |
TGA |
Arg |
Stop |
SM |
NCI-H1793 |
14 |
Lung (NSCLC) |
92 |
Controversy with other publications |
273 |
CGT |
CAT |
Arg |
His |
SM |
NCI-H1793 |
780 |
Lung (NSCLC) |
2249 |
Controversy with other publications |
158 |
CGC |
CTC |
Arg |
Leu |
SM |
NCI-H226 |
92 |
Lung (NSCLC) |
92 |
Controversy with other publications |
309 |
CCC |
GCC |
Pro |
Ala |
SM |
NCI-H226 |
1 |
Lung (NSCLC) |
1018 |
Controversy with other publications |
249 |
AGG |
AGC |
Arg |
Ser |
SM |
NCI-H324 |
34 |
Lung (NSCLC) |
678 |
Controversy with other publications |
249 |
AGG |
AGC |
Arg |
Ser |
DMU |
NCI-H324 |
34 |
Lung (NSCLC) |
92 |
Controversy with other publications |
259 |
GAC |
GTC |
Asp |
Val |
DMU |
NCI-H324 |
21 |
Lung (NSCLC) |
92 |
Controversy with other publications |
248 |
CGG |
TGG |
Arg |
Trp |
SM |
PC-14 |
728 |
Lung (NSCLC) |
1382 |
Controversy with other publications |
248 |
CGG |
CAG |
Arg |
Gln |
SM |
PC-14 |
883 |
Lung (NSCLC) |
2242 |
Controversy with other publications |
280 |
AGA |
AAA |
Arg |
Lys |
SM |
SK-MES-1 |
78 |
Lung (NSCLC) |
1081 |
Controversy with other publications. Excluded from the cosnensus |
298 |
GAG |
TAG |
Glu |
Stop |
SM |
SK-MES-1 |
71 |
Lung (NSCLC) |
303 |
Consensus based on three publications. Controversy with other publications |
46 |
TCC |
del1b |
Ser |
Fs. |
DMU |
NCI-H1048 |
1 |
Lung (SCLC) |
2249 |
Controversy with other publications |
273 |
CGT |
TGT |
Arg |
Cys |
SM |
NCI-H1048 |
687 |
Lung (SCLC) |
22 |
Controversy with other publications |
273 |
CGT |
TGT |
Arg |
Cys |
DMU |
NCI-H1048 |
687 |
Lung (SCLC) |
2249 |
Controversy with other publications |
258 |
GAA |
AAA |
Glu |
Lys |
DMU |
MeWo |
73 |
Melanoma |
2249 |
Controversy with other publications |
258 |
GAA |
AAA |
Glu |
Lys |
SM |
MeWo |
73 |
Melanoma |
1076 |
Controversy with other publications |
317 |
CAG |
TAG |
Gln |
Stop |
DMU |
MeWo |
25 |
Melanoma |
2249 |
Controversy with other publications |
341 |
TTC |
TTT |
Phe |
Phe |
SM |
MeWo |
4 |
Melanoma |
2019 |
Controversy with other publications |
342 |
CGA |
TGA |
Arg |
Stop |
SM |
MeWo |
74 |
Melanoma |
2019 |
Controversy with other publications |
239 |
AAC |
GAC |
Asn |
Asp |
SM |
PA-1 |
53 |
Ovarian carcinoma |
854 |
Controversy with other publications. wt in COSMIC |
316 |
CCC |
CCT |
Pro |
Pro |
SM |
PA-1 |
6 |
Ovarian carcinoma |
144 |
Controversy with other publications. wt in COSMIC |
89 |
CCC |
del1a |
Pro |
Fs. |
SM |
SK-OV-3 |
3 |
Ovarian carcinoma |
2249 |
Controversy with other publications |
179 |
CAT |
CGT |
His |
Arg |
SM |
SK-OV-3 |
146 |
Ovarian carcinoma |
1018 |
Controversy with other publications |
262 |
GGT |
GTT |
Gly |
Val |
SM |
SW626 |
14 |
Ovarian carcinoma |
864 |
Controversy with other publications |
273 |
CGT |
CAT |
Arg |
His |
SM |
SW626 |
780 |
Ovarian carcinoma |
1011 |
Controversy with other publications |
134 |
TTT |
del1a |
Phe |
Fs. |
SM |
AsPC-1 |
4 |
Pancreatic cancer |
397 |
Consensus based on four publications. Controversy with other publications |
273 |
CGT |
CAT |
Arg |
His |
SM |
ASPC-1 |
780 |
Pancreatic cancer |
132 |
Controversy with other publications. Excluded from the consensus |
273 |
CGT |
CAT |
Arg |
His |
SM |
Panc-1 |
780 |
Pancreatic cancer |
178 |
Consensus based on four publications. Controversy with one publication |
273 |
CGT |
TGT |
Arg |
Cys |
SM |
Panc-1 |
687 |
Pancreatic cancer |
177 |
Controversy with other publications. Excluded from the cosnensus |
223 |
CCT |
CTT |
Pro |
Leu |
DMD |
DU-145 |
5 |
Prostate ca. |
59 |
Consensus based on three publications. Controvery withy other publications (only one of the two mutations is found) |
274 |
GTT |
TTT |
Val |
Phe |
DMD |
DU-145 |
32 |
Prostate ca. |
59 |
Consensus based on three publications. Controvery withy other publications (only one of the two mutations is found) |
278 |
CCT |
GCT |
Pro |
Ala |
DMU |
786-0 |
24 |
Renal cell ca. |
1018 |
Controversy with other publications. Splice in COSMIC |
273 |
CGT |
TGT |
Arg |
Cys |
SM |
Rh30 |
687 |
Rhabdomyosarcoma |
1190 |
Controversy with other publications |
280 |
AGA |
AGT |
Arg |
Ser |
SM |
RH30 |
14 |
Rhabdomyosarcoma |
97 |
Controversy with other publications |
111 |
CTG |
GTG |
Leu |
Val |
SM |
MOLT-4 |
1 |
T-cell Acute Lymphoblastic Leu |
2242 |
Controversy with other publications |
248 |
CGG |
CAG |
Arg |
Gln |
SM |
MOLT-4 |
883 |
T-cell Acute Lymphoblastic Leu |
27 |
Controversy with other publications |
306 |
CGA |
TGA |
Arg |
Stop |
SM |
MOLT-4 |
160 |
T-cell Acute Lymphoblastic Leu |
2249 |
Controversy with other publications |